Articles from Remix Therapeutics

Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Mythili Koneru, MD, PhD, as Chief Medical Officer. Dr. Koneru will lead clinical development, medical strategy, and regulatory engagement as the company advances its pipeline, including first-in-class oral small molecule mRNA degrader, REM-422, through clinical development and regulatory milestones.

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025 at 2:15 PM ET

Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population

Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of life science executive, Linda C. Bain, to its Board of Directors. Ms. Bain is a Venture Partner at Atlas Venture and currently serves as a Board Advisor to Remix Therapeutics.

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 1:00 p.m. ET.

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that its management team will host one-on-one meetings with investors at the Leerink Global Healthcare Conference on Monday, March 10, 2025 in Miami, FL.

Company to Announce Lead Program During Podium Presentation